en · de · es · fr · pt
cardarine-notes.peptides1126.com › Faq › Preclinical Findings And Safety Signals — Worked Examples

Preclinical Findings And Safety Signals — Worked Examples

By Editorial Desk · published 2025-10-23 · last reviewed 2025-12-11 · Faq

A practical reference on Prohibited list: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-12-11 and is reviewed periodically as new material appears.

Preclinical Findings and Safety Signals

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Mechanism and Detection

Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.

Cardarine at a glance

PropertyValueNotes
Primary targetPPARδ (NR1C2)Nuclear receptor involved in lipid metabolism
Preclinical effectIncreased fatty acid oxidationObserved in rodent studies
Key safety signalTumors in rodents after long-term exposureContributed to halted clinical development
Human trial statusNo approved product; development stoppedLimited short-term metabolic data
Sport regulatory statusProhibited at all timesWADA hormone and metabolic modulators class

Detection and Regulatory Landscape

Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.

Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.

Related pages on this site

Background and Regulatory History

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

Identity and Regulatory Status

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Mechanism and Detection Methods

Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.

Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.

Background from the literature

=== Discovery and synthesis === The hormonal action of progesterone was discovered in 1929. Pure crystalline progesterone was isolated in 1934 and its chemical structure was determined. Later that year, chemical synthesis of progesterone was accomplished. Shortly following its chemical synthesis, progesterone began being tested clinically in women.

=== tio === tiocarlide (INN) tioclomarol (INN) tioconazole (INN) tioctilate (INN) Tiocystin tiodazosin (INN) tiodonium chloride (INN) tioguanine (INN) tiomergine (INN) tiomesterone (INN) tiomolibdate diammonium (USAN) tiomolibdic acid (USAN) tioperidone (INN) tiopinac (INN) tiopronin (INN) tiopropamine (INN) tiosalan (INN) tiospirone (INN) tiotidine (INN) tiotixene (INN) tiotropium bromide (INN) tioxacin (INN) tioxamast (INN) tioxaprofen (INN) tioxidazole (INN) tioxolone (INN)

=== Variation === The sternalis muscle may be a variant form of the pectoralis major or the rectus abdominis. Some fibers are occasionally connected with the costoxiphoid ligaments, and the side of the xiphoid process.

In addition, microfluidics-based devices, capable of continuous sampling and real-time testing of air/water samples for biochemical toxins and other dangerous pathogens, can serve as an always-on "bio-smoke alarm" for early warning. Microfluidic technology has provide tools for biologists to control the cellular environment. Potential advantages of this technology for microbiology are listed below:

Sources: en.wikipedia.org

Further detail

== Thenford gardens and arboretum == The Heseltines purchased Thenford House and its grounds in 1976. The house was bought privately with the aid of a large loan, and they are thought to have paid around £750,000 (approximately £7.58m at 2025, RPI prices), and to have spent a similar sum on renovating the property. They also own a number of farms in the area. Over the next 25 years they restored 40 acres (16 ha) of woodland together with the walled garden, medieval fish-ponds, and a 2 acres (0.81 ha) lake. There is also a sculpture garden, which includes a large bronze bust of Lenin, from Latvia. At the turn of the century they decided to create various ornamental features in the garden and increase the range of trees and shrubs in the arboretum. Covering over 70 acres (28 ha) the arboretum is stocked with over 3,000 different species. Their arboretum was featured in a one-off documentary on BBC Two in December 2005. In October 2016 the Heseltines were featured on BBC's Gardeners' World, discussing their garden at Thenford House, parts of which were modelled after the gardens at Château de Villandry. The garden is open to the public by appointment only.

=== Nitric oxide === Nitric oxide (NO) is a major source of immunomodulation in rodents, and is produced by enzyme nitric oxide synthetase type 2 (NOS2) in the alveolar macrophage. NO inhibits tyrosine phosphorylation of the kinases involved in production of the interleukin-2 (IL-2) receptor, the expression of which is fundamental for T cell proliferation. In humans, however, NOS2 activity has been difficult to verify. There are two explanations for the lack of responsiveness in the promoter of human inducible nitric oxide synthetase (iNOS) to NO activation by lipopolysaccharides (LPS) + interferon gamma (IFNγ). The first is that there are various inactivating nucleotide variations in the human counterpart of the enhancer element that regulates LPS/IFNγ induced expression of the mouse NOS2 gene. The second is because of the absence of a nuclear factor in human macrophages that is required for optimum expression of gene NOS2 (LPS-inducible nuclear factor-kappa B/Rel complex). It is assumed that the difficulty in verifying NOS2 is due to a much more tightly controlled expression in human AMs as compared to that in the rodent AMs. NOS2 is part of an autoregulatory feedback loop, wherein an allergen or provoker stimulates inflammatory cytokine production, which in turn stimulates NO production, and NO down-regulates cytokine production.

On 21 March 2020, Bukele imposed a 30-day nationwide lockdown in an effort to combat the pandemic. During the lockdown, 4,236 people were arrested by the National Civil Police for violating the lockdown order; 70 were arrested before the lockdown order became public. The arrestees were quarantined in a "containment center". Human rights organizations such as Human Rights Watch criticized the arrests, citing instances of arbitrary arrests and abuse by police. Amid April 2020 lockdowns in the country's prisons and published images of prisoners lined up in cramped positions, Human Rights Watch called the prisons' living conditions "inhumane" (particularly in light of the pandemic). On 27 May 2020, the United States donated 250 ventilators to El Salvador. During a press conference where Bukele received the ventilators, he said that he took hydroxychloroquine as prophylaxis and added that "most of the world's leaders use [hydroxychloroquine] as a prophylaxis". Bukele inaugurated the Hospital El Salvador, the largest hospital in Latin America used exclusively for treating cases of COVID-19 at the site of the former International Center for Fairs and Conventions, on 22 June 2020. The hospital had a capacity of 400 beds, 105 intensive-care units, and 295 intermediate-care units staffed by 240 doctors. In August 2020, the hospital's capacity was increased by 575 beds. It began treating conditions other than COVID-19 by June 2022.

Sources: en.wikipedia.org

Background from the literature

=== Opposable thumbs === Opposable thumbs allowing the grasping of objects are most often associated with primates, like humans and other apes, monkeys, and lemurs. Opposable thumbs also evolved in giant pandas, but these are completely different in structure, having six fingers including the thumb, which develops from a wrist bone entirely separately from other fingers.

In the following years, it became the basis for the prosecutions of the opposition and the officers during the imposition of the totalitarian regime in the country. Between 23 and 31 January, Kimon Georgiev visited Moscow, where he met Joseph Stalin and Georgi Dimitrov for the first time. The main purpose of the visit was the conclusion, with Soviet mediation, of an alliance treaty between Bulgaria and Yugoslavia. Secret letters to the treaty envisaged the future creation of a federation, without specifying whether on an equal basis between the two countries, which Bulgaria insisted on, or by incorporating Bulgaria into Yugoslavia as a sixth republic, which was the Yugoslav position. The treaty was never concluded because of the opposition of the United Kingdom and the United States, who believed that Bulgaria could not act independently until a peace treaty was concluded. On 9 February 1945, Kimon Georgiev gave a report on the government's work to the First Congress of the Fatherland Front. Days after the first executions under the decision of the so-called People's Court, he deplored the "cases of self-destruction, arbitrariness and violence" that had been allowed to take place, claimed that they had been curbed quickly, and expressed satisfaction at their being channeled through the People's Court. He states that the constitution and "the rights and liberties of the Bulgarian people" have been restored, although the Council of Ministers rules by ordinance-laws and political organizations outside the Fatherland Front have not been legalized.

== Mechanism of catalysis == The molecular mechanism of O-linked N-acetylglucosamine transferase has not been extensively studied either, since there is not a confirmed crystal structure of the enzyme. A proposed mechanism by Lazarus et al. is supported by product inhibition patterns of UDP at saturating peptide conditions. This mechanism proceeds with starting materials Uridine diphosphate N-acetylglucosamine, and a peptide chain with a reactive serine or threonine hydroxyl group. The proposed reaction is an ordered sequential bi-bi mechanism.

Polyphenols comprise up to 0.2–0.3% fresh weight for many fruits. Consuming common servings of wine, chocolate, legumes or tea may also contribute to about one gram of intake per day. According to a 2005 review on polyphenols:

Sources: en.wikipedia.org

Frequently asked questions

What did animal studies show?

Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.

Has cardarine been tested in humans?

Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.

Does cardarine improve athletic performance in people?

Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.

How does cardarine work in the body?

It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.

Network